The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
|Videos|January 2, 2014
The Outlook for JAK Inhibitors in Myelofibrosis
Author(s)Ayalew Tefferi, MD
Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the outlook for JAK inhibitors for patients with myelofibrosis.
Advertisement
Clinical Pearls
Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the outlook for JAK inhibitors for patients with myelofibrosis.
- No JAK inhibitor can elicit PR or CR in myelofibrosis
- JAK inhibitors have good palliative value and are able to help a patient gain weight and shrink their spleen
- An oncologist wants to cure cancer or put it to sleep JAK inhibitors will never rise to that level
- There remains a need for pilot studies with innovative drugs that could potentially clear cancer
Advertisement
Related to this article
New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.
The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall survival.
Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
3
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
4
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
5